Eiger BioPharmaceuticals, Inc. (EIGR)

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas.

Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria Eiger to receive $500,000 approval milestone payment from AnGes Zokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024) PALO ALTO, Calif. , Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).

PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split").

Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. According to a press release from the company, it has discontinued its Phase 3 LIMT-2 study.

PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD).

PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C.

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian, MD, PhD, MBA, appointed CEO PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the second quarter 2023 and provided a business update.

Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way.

The stock price of Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) surged by 23.53% today. This is why.

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Penny stocks to watch before next year. The post Best Penny Stocks To Buy?

Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.

Today, we revisit the investment case around Eiger BioPharmaceuticals for the first time in more than a year and a half. Eiger has one product on the market and is rapidly advancing a powerful 'sum of the parts' story.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - President and CEO Sri Ryali - Chief Financial Officer Eldon Mayer - Chief Commercial Officer Ingrid Choong - Senior Vice President, Clinical Development Colin Hislop - Senior Vice President, Clinical & Development Operations Colleen Craig - Vice President, Metabolic Diseases Conference Call Participants Maury Raycroft - Jefferies Charlie Moore - Baird Bert Hazlett - BTIG Farhana Sakloth - Ladenburg Operator Welcome to the Eiger BioPharmaceuticals Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.